CSL Ltd
ASX:CSL
Intrinsic Value
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. [ Read More ]
The intrinsic value of one CSL stock under the Base Case scenario is 235.8 AUD. Compared to the current market price of 278.45 AUD, CSL Ltd is Overvalued by 15%.
Valuation Backtest
CSL Ltd
Run backtest to discover the historical profit from buying and selling CSL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
CSL Ltd
Current Assets | 10.1B |
Cash & Short-Term Investments | 1B |
Receivables | 3.6B |
Other Current Assets | 5.6B |
Non-Current Assets | 27.2B |
Long-Term Investments | 161m |
PP&E | 9.6B |
Intangibles | 16.5B |
Other Non-Current Assets | 968m |
Current Liabilities | 4.7B |
Accounts Payable | 2.9B |
Short-Term Debt | 6m |
Other Current Liabilities | 1.8B |
Non-Current Liabilities | 15.4B |
Long-Term Debt | 10.7B |
Other Non-Current Liabilities | 4.7B |
Earnings Waterfall
CSL Ltd
Revenue
|
14.2B
USD
|
Cost of Revenue
|
-6.9B
USD
|
Gross Profit
|
7.3B
USD
|
Operating Expenses
|
-3.7B
USD
|
Operating Income
|
3.7B
USD
|
Other Expenses
|
-1.2B
USD
|
Net Income
|
2.5B
USD
|
Free Cash Flow Analysis
CSL Ltd
CSL Profitability Score
Profitability Due Diligence
CSL Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
CSL Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
CSL Solvency Score
Solvency Due Diligence
CSL Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
CSL Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CSL Price Targets Summary
CSL Ltd
According to Wall Street analysts, the average 1-year price target for CSL is 307.59 AUD with a low forecast of 233.7 AUD and a high forecast of 355.43 AUD.
Shareholder Return
CSL Price
CSL Ltd
Average Annual Return | 11.59% |
Standard Deviation of Annual Returns | 19.67% |
Max Drawdown | -30% |
Market Capitalization | 134.5B AUD |
Shares Outstanding | 484 984 333 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 25,000 full-time employees. The firm is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. The company offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The firm operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.
Contact
IPO
Employees
Officers
The intrinsic value of one CSL stock under the Base Case scenario is 235.8 AUD.
Compared to the current market price of 278.45 AUD, CSL Ltd is Overvalued by 15%.